Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketotifen and Indomethacin for Mild to Moderate COVID-19
NCT05007522Phase 3Completed
- Sponsor
- Sen-Jam Pharmaceutical
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketotifen, indomethacin in coronavirus disease 2019 (COVID-19), sponsored by Sen-Jam Pharmaceutical. Started May 2022; status: completed.
02
Drugs
ketotifenindomethacin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05007522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007522.